Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

Advanced non-small cell lung cancer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibody-Drug Conjugates (ADCs) (1) c-Met/HGFR (2) CD73 (1) EGFR (3) Folate Receptor (FR) (1) Isotope-Labeled Compounds (2) PD-1/PD-L1 (3) Peptide-Drug Conjugates (PDCs) (1) Ras (5) Topoisomerase (1) Transmembrane Glycoprotein (1) TRP Channel (1) VEGFR (2)
By Research Areas:	Cancer (16) Inflammation/Immunology (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Targets Recommended: Small Interfering RNA (siRNA) Programmed Cell Death 4 (PDCD4) TNK1 BCRP Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor VISTA BCL6 Tim3 BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9903

Nivolumab 20+ Cited Publications BMS-936558; ONO-4538; MDX-1106	PD-1/PD-L1	Cancer
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

HY-112870

Firmonertinib 4 Publications Verification Alflutinib; Furmonertinib; AST2818	EGFR	Cancer
Firmonertinib (Alflutinib; Furmonertinib) is an orally active, mutant-selective, and highly brain penetrant EGFR inhibitor. Firmonertinib inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation .

HY-112870A

Firmonertinib mesylate 4 Publications Verification Alflutinib mesylate; Furmonertinib mesylate; AST2818 mesylate	EGFR	Cancer
Firmonertinib (Alflutinib; Furmonertinib) mesylate is is an orally active, mutant-selective, and highly brain penetrant EGFR inhibitor. Firmonertinib mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib mesylate has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation .

HY-19815

Olafertinib CK-101; RX518	EGFR	Cancer
Olafertinib (CK-101) is an orally available, third generation and irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Olafertinib selectively inhibits both EGFR-TKI-sensitizing and resistance mutations with minimal activity on wild-type EGFR. Olafertinib can be used in research for non-small cell lung cancer (NSCLC) with EGFR mutations and other advanced malignancies .

HY-114277

Sotorasib Maximum Cited Publications 77 Publications Verification AMG-510	Ras	Cancer
Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC) .

HY-P991628

SSGJ-707	PD-1/PD-L1 VEGFR	Cancer
SSGJ-707 is a bispecific, recombinant humanized IgG4 monoclonal antibody inhibitor targeting PD-1 and VEGF. SSGJ-707 can be used for cancers research, such as advanced non-small cell lung cancer (NSCLC) and recurrent endometrial cancer

HY-P991620

JS006	Transmembrane Glycoprotein	Cancer
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .

HY-164493

KRASG12C IN-13	Ras	Cancer
KRASG12C IN-13 (LY3499446) is a potent KRAS G12C inhibitor. KRASG12C IN-13 is promising for research of advanced solid tumors including non-small cell lung cancer and colorectal cancer .

HY-P991612

S095024 Sym024	CD73	Inflammation/Immunology Cancer
S095024 is a humanized IgG1 monoclonal antibody inhibitor targeting CD73. S095024 can be used to study acute respiratory distress syndrome (ARDS), non-small cell lung cancer (NSCLC) and advanced solid tumor malignancies .

HY-P10762

Ricorfotide vedotin CBP-1008; LDC 10B	Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel	Cancer
Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .

HY-174387

KIN-8741	c-Met/HGFR	Cancer
KIN-8741 is a highly selective Type IIb c-Met inhibitor. KIN-8741 has broad activity against c-Met kinase mutations. KIN-8741 shows antitumor activity in MET gene amplified and exon 14 deleted non-small cell lung cancer models. KIN-8741 can be used in the research of c-Met driven cancers, especially advanced tumors carrying MET exon 14 jump mutations, acquired drug resistance mutations, etc .

HY-P99675

Ivonescimab AK112	PD-1/PD-L1 VEGFR	Cancer
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL) .

HY-114277R

Sotorasib (Standard)	Ras	Cancer
Sotorasib (Standard) is the analytical standard of Sotorasib. This product is intended for research and analytical applications. Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC) .

HY-114277S

Sotorasib-d7 AMG-510-d₇	Isotope-Labeled Compounds Ras	Cancer
Sotorasib-d₇ (AMG-510-d₇) is a deuterium-labeled Sotorasib (HY-114277). Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC) .

HY-114277S2

Sotorasib-d3 AMG-510-d₃	Isotope-Labeled Compounds Ras	Cancer
Sotorasib-d₃ (AMG-510-d₃) is deuterium labeled Sotorasib. Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C?mutated locally advanced or metastatic non?small cell lung cancer (NSCLC) .

HY-171945

Telisotuzumab Adizutecan ABBV-400; Temab-A	Antibody-Drug Conjugates (ADCs) Topoisomerase c-Met/HGFR	Cancer
Telisotuzumab Adizutecan (ABBV-400) is an anti- c-Met antibody-drug conjugate (ADC). Telisotuzumab Adizutecan consists of a humanized anti-c-Met antibody Telisotuzumab (HY-P99391), a stable and cleavable linker (TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane), a topoisomerase 1 inhibitor (7-MAD-MDCPT) (HY-132162), and the drug-linker conjugate for ADC is TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT (HY-171946). Telisotuzumab Adizutecan has a significant anti-tumor activity in advanced solid tumors, such as colorectal, gastric and non-small cell lung cancer .

Cat. No.	Product Name	Target	Research Area

HY-P10762

Ricorfotide vedotin CBP-1008; LDC 10B	Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel	Cancer
Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .

Cat. No.	Product Name	Target	Research Area

HY-P9903

Nivolumab 20+ Cited Publications BMS-936558; ONO-4538; MDX-1106	PD-1/PD-L1	Cancer
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

HY-P99675

Ivonescimab AK112	PD-1/PD-L1 VEGFR	Cancer
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL) .

HY-P991628

SSGJ-707	PD-1/PD-L1 VEGFR	Cancer
SSGJ-707 is a bispecific, recombinant humanized IgG4 monoclonal antibody inhibitor targeting PD-1 and VEGF. SSGJ-707 can be used for cancers research, such as advanced non-small cell lung cancer (NSCLC) and recurrent endometrial cancer

HY-P991620

JS006	Transmembrane Glycoprotein	Cancer
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .

HY-P991612

S095024 Sym024	CD73	Inflammation/Immunology Cancer
S095024 is a humanized IgG1 monoclonal antibody inhibitor targeting CD73. S095024 can be used to study acute respiratory distress syndrome (ARDS), non-small cell lung cancer (NSCLC) and advanced solid tumor malignancies .

Cat. No.	Product Name	Chemical Structure

HY-114277S

Sotorasib-d7
Sotorasib-d₇ (AMG-510-d₇) is a deuterium-labeled Sotorasib (HY-114277). Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC) .

Sotorasib-d7

Sotorasib-d₇ (AMG-510-d₇) is a deuterium-labeled Sotorasib (HY-114277). Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC) .

HY-114277S2

Sotorasib-d3
Sotorasib-d₃ (AMG-510-d₃) is deuterium labeled Sotorasib. Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C?mutated locally advanced or metastatic non?small cell lung cancer (NSCLC) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.